BACKGROUND: Increased duration of hormonal contraceptive (HC) use may be positively associated with the risk of invasive cervical cancer. METHODS: This is a secondary analysis from the HPV Sentinel Surveillance Study. The authors examined the association between type-specific human papillomavirus (HPV) detection and current HC use among 7718 women attending 26 sexually transmitted disease, family planning and primary care clinics in the USA. RESULTS: There was an association between HC use and HPV-16 detection (adjusted prevalence rate ratio 1.34 (95% CI 1.05 to 1.71) for oral contraceptive users and 1.41 (1.01 to 2.04) for depot-medroxyprogesterone acetate users); there was no association between HC use and detection of other HPV types or any HPV overall. CONCLUSIONS: Longitudinal studies are needed to better define this type-specific association and its clinical significance.
BACKGROUND: Increased duration of hormonal contraceptive (HC) use may be positively associated with the risk of invasive cervical cancer. METHODS: This is a secondary analysis from the HPV Sentinel Surveillance Study. The authors examined the association between type-specific human papillomavirus (HPV) detection and current HC use among 7718 women attending 26 sexually transmitted disease, family planning and primary care clinics in the USA. RESULTS: There was an association between HC use and HPV-16 detection (adjusted prevalence rate ratio 1.34 (95% CI 1.05 to 1.71) for oral contraceptive users and 1.41 (1.01 to 2.04) for depot-medroxyprogesterone acetate users); there was no association between HC use and detection of other HPV types or any HPV overall. CONCLUSIONS: Longitudinal studies are needed to better define this type-specific association and its clinical significance.
Authors: Anil K Chaturvedi; Leann Myers; Ansley F Hammons; Rebecca A Clark; Kathleen Dunlap; Patricia J Kissinger; Michael E Hagensee Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-10 Impact factor: 4.254
Authors: Victor Moreno; F Xavier Bosch; Nubia Muñoz; Chris J L M Meijer; Keerti V Shah; Jan M M Walboomers; Rolando Herrero; Silvia Franceschi Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: Morgan A Marks; Patti E Gravitt; Robert D Burk; Yevgeniy Studentsov; Homayoon Farzadegan; Sabra L Klein Journal: Clin Vaccine Immunol Date: 2010-02-03
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky Journal: Am J Epidemiol Date: 2003-02-01 Impact factor: 4.897
Authors: J Green; A Berrington de Gonzalez; J S Smith; S Franceschi; P Appleby; M Plummer; V Beral Journal: Br J Cancer Date: 2003-06-02 Impact factor: 7.640
Authors: Rebecca M Brotman; Michelle D Shardell; Pawel Gajer; J Kathleen Tracy; Jonathan M Zenilman; Jacques Ravel; Patti E Gravitt Journal: J Infect Dis Date: 2014-06-18 Impact factor: 5.226
Authors: Rachel L Winer; James P Hughes; Qinghua Feng; Joshua E Stern; Long Fu Xi; Laura A Koutsky Journal: J Infect Dis Date: 2016-03-23 Impact factor: 5.226
Authors: Carolina Mm Amaral; Katerina Cetkovská; Ana Pad Gurgel; Marcus V Cardoso; Bárbara S Chagas; Sérgio Sl Paiva Júnior; Rita de Cássia Pereira de Lima; Jacinto C Silva-Neto; Luiz Af Silva; Maria Tc Muniz; Valdir Q Balbino; Antonio C Freitas Journal: Infect Agent Cancer Date: 2014-07-18 Impact factor: 2.965
Authors: Admire Chikandiwa; Helen Kelly; Bernard Sawadogo; Jean Ngou; Pedro T Pisa; Lorna Gibson; Marie-Noelle Didelot; Nicolas Meda; Helen A Weiss; Michel Segondy; Philippe Mayaud; Sinead Delany-Moretlwe Journal: PLoS One Date: 2018-05-01 Impact factor: 3.240